

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HOFLAND et al.

Atty. Ref.: 620-454

Serial No. unknown

TC/A.U.: unknown

Filed: September 5, 2006

Examiner: Unknown

For: CANCER TREATMENT WITH TOPOISOMERASE-II INHIBITOR, A BIS-DIOXYPIPERAZINE AND RADIATION

* * * * *

September 5, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO/SB/08a. Copies of the International Search Report and cited foreign and literature documents are attached.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


B.J. Sadoff
Reg. No. 36,663

BJS:alb
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IAP12 Rec'd PCT/PTO 05 SEP 2006

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-454

unknown 10/591847

APPLICANT

HOFLAND et al.

(Use several sheets if necessary)

FILING DATE

TC/A.U.

September 5, 2006

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,963,551	10/1990	PALEPU et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
97/25044	07/1997	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report of PCT/IB2005/000670, mailed 6 April 2006
	SCHROEDER et al., "Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent", Cancer Chemotherapy and Pharmacology, Vol. 53, No. 1, January 2004, Pgs. 91-93, XP008061658
	SCHROEDER et al., "Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide", Cancer Chemotherapy and Pharmacology, Vol. 52, No. 2, August 2003, Pgs. 167-174, XP008061654
	HOLM B et al., "Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide", Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, June 1998, Vol. 4, No. 6, June 1998, Pgs. 1367-1373, XP002373086
	JENSEN et al., "DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide", Biochemical Pharmacology, 1 October 1997, Vol. 54, No. 7, Pgs. 755-759, XP008061671
	HOLM BENTE et al., "ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors", Cancer Chemotherapy and Pharmacology, Vol. 38, No. 3, 1996, Pgs. 203-209, XP008061672
	MINEHAN KERN et al., "The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment", Life Sciences, Vol. 53, No. 15, 1993, Pgs. 237-242, XP008061879

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.